LADENBURG THALM/SH SH Downgrades Traws Pharma (NASDAQ:TRAW) to Neutral

Traws Pharma (NASDAQ:TRAW) was downgraded by equities research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, Marketbeat.com reports.

Several other research firms also recently weighed in on TRAW. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Traws Pharma in a research report on Wednesday, May 20th. Citigroup downgraded Traws Pharma to a “neutral” rating in a research report on Monday. Finally, Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Traws Pharma has a consensus rating of “Hold” and a consensus target price of $8.00.

Traws Pharma Stock Performance

NASDAQ:TRAW opened at $1.28 on Monday. Traws Pharma has a twelve month low of $1.00 and a twelve month high of $3.27. The company has a market cap of $13.00 million, a price-to-earnings ratio of -0.76 and a beta of 1.45. The stock has a fifty day simple moving average of $1.49 and a 200-day simple moving average of $1.74.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.39. As a group, equities research analysts predict that Traws Pharma will post -2.23 EPS for the current fiscal year.

Insider Buying and Selling at Traws Pharma

In other news, major shareholder Orbimed Advisors Llc bought 597,729 shares of Traws Pharma stock in a transaction on Thursday, April 16th. The stock was acquired at an average cost of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the acquisition, the insider owned 1,203,250 shares of the company’s stock, valued at $2,009,427.50. This trade represents a 98.71% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.57% of the stock is owned by insiders.

Hedge Funds Weigh In On Traws Pharma

Hedge funds have recently modified their holdings of the stock. State Street Corp acquired a new position in Traws Pharma in the 4th quarter worth approximately $29,000. Two Sigma Investments LP increased its holdings in Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after buying an additional 5,955 shares during the period. XTX Topco Ltd increased its holdings in Traws Pharma by 294.2% in the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after buying an additional 31,502 shares during the period. Seven Fleet Capital Management LP acquired a new position in Traws Pharma in the 4th quarter worth approximately $56,000. Finally, Geode Capital Management LLC increased its holdings in Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after buying an additional 18,213 shares during the period. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.